Drugs / SIM0613
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07618260 | May 2026 → Jun 2028 expected | cancer | Jiangsu Simcere Pharmaceutical Co., Ltd. | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2026-05-06 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Regulatory Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China simcere.com ↗
has received the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2026-06-03 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Zaiming Announces First Patient Enrolled in Phase I Clinical Trial of Anti-LRRC15 ADC SIM0613 simcere.com ↗ |
| 2026-05-06 | Jiangsu Simcere Pharmaceutical Co., Ltd. | Simcere Zaiming’s LRRC15-Targeting ADC SIM0613 Receives IND Approval in China simcere.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SIM0613 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07618260 ↗ |
| Route | Intravenous | “Administered as an intravenous infusion in dosing cycles” NCT07618260 ↗ |